- Home
- URG vs LXRX Comparison
URG vs LXRX Comparison
Compare URG & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URG
- LXRX
- Stock Information
- Founded
- URG 2004
- LXRX 1995
- Country
- URG United States
- LXRX United States
- Employees
- URG N/A
- LXRX 103
- Industry
- URG Precious Metals
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- URG Basic Materials
- LXRX Health Care
- Exchange
- URG Nasdaq
- LXRX Nasdaq
- Market Cap
- URG 541.7M
- LXRX 541.5M
- IPO Year
- URG N/A
- LXRX 2000
- Fundamental
- Price
- URG $1.20
- LXRX $1.46
- Analyst Decision
- URG Strong Buy
- LXRX Buy
- Analyst Count
- URG 5
- LXRX 5
- Target Price
- URG $2.52
- LXRX $3.23
- AVG Volume (30 Days)
- URG 8.6M
- LXRX 2.2M
- Earning Date
- URG 11-03-2025
- LXRX 11-06-2025
- Dividend Yield
- URG N/A
- LXRX N/A
- EPS Growth
- URG N/A
- LXRX N/A
- EPS
- URG N/A
- LXRX N/A
- Revenue
- URG $39,411,000.00
- LXRX $70,864,000.00
- Revenue This Year
- URG N/A
- LXRX $66.55
- Revenue Next Year
- URG $199.04
- LXRX N/A
- P/E Ratio
- URG N/A
- LXRX N/A
- Revenue Growth
- URG 138.94
- LXRX 1255.21
- 52 Week Low
- URG $0.55
- LXRX $0.28
- 52 Week High
- URG $2.35
- LXRX $1.66
- Technical
- Relative Strength Index (RSI)
- URG 30.20
- LXRX 53.11
- Support Level
- URG $1.26
- LXRX $1.18
- Resistance Level
- URG $1.34
- LXRX $1.64
- Average True Range (ATR)
- URG 0.09
- LXRX 0.12
- MACD
- URG -0.04
- LXRX 0.01
- Stochastic Oscillator
- URG 6.78
- LXRX 59.78
About URG Ur Energy Inc (Canada)
Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.